Journal of Contemporary Medicine (Nov 2022)

A Pilot Study on the Performance of Presepsin in Acute Appendicitis: A Prospective Case-Control Study

  • Medine Taşar,
  • Mehmet Şeneş,
  • Gizem Çalık,
  • Nihal Avcı,
  • Özkan Cesur,
  • İsmail Bulut,
  • İlknur Fidancı,
  • Serçin Taşar

DOI
https://doi.org/10.16899/jcm.1170883
Journal volume & issue
Vol. 12, no. 6
pp. 859 – 865

Abstract

Read online

Aim: Diagnostic biomarkers are needed for pediatric acute appendicitis (AA). We hypothesized that presepsin (soluble CD14 subtype), a biomarker for sepsis, can also be used in pediatric AA and aimed to investigate its diagnostic value in those patients. Materials and Methods: This prospective case-control study was conducted on children admitted to the Pediatric Emergency Department with suspected acute appendicitis. Serum levels of interleukin-6, and presepsin were statistically analyzed for their diagnostic values. Results: No remarkable demographic differences were present between the 41 cases and 47 controls. Clinical and routine laboratory findings were significantly positive for acute appendicitis in the cases compared to controls. ROC analysis indicated an AUC for presepsin as 0.999 (CI 95%: 0.890-0.993) and for interleukin-6 as 0.963 (CI 95%:0.949-1.000). The best cut-off point value for presepsin was at 739 pg/ml, corresponding to a sensitivity of 97.56% and a specificity of 100%. The best cut-off point value for interleukin-6 was at 19 pg/ml, corresponding to a sensitivity of 97.56% and a specificity of 90.32%. Conclusions: Our study results indicate that presepsin can be considered a biomarker for diagnosing appendicitis in pediatric cases. Future studies might better include the combination with other biomarkers in pediatric cases.

Keywords